Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714817 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 695
- Enrollment target
NCT01714817: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT01714817 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 695 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714817, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 695 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)
Primary Outcome
Number of participants achieving CR was divided by the total number of participants in that arm and expressed as a percentage. CR defined as: eGFR is normal or no \<85% of the baseline; eGFR based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equiv. for at least 28 days prior to assessment. Participants with \>10mg/day prednisone or equivalent for non-renal disease w
Interventions
- DRUG Prednisone
- DRUG Mycophenolate mofetil
- BIOLOGICAL BMS-188667
- BIOLOGICAL Placebo matching with BMS-188667
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 695 participants |
| Start Date | 2013-01-22 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 3 |
Why NCT01714817 stopped before completion
NCT01714817 is an interventional study that assigns participants to a tested intervention. The registered 695 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT01714817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01714817 about?
NCT01714817 is a clinical study titled "Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis". The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)
What is the current status of trial NCT01714817?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 695 participants. The study started on 2013-01-22. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT01714817?
The interventions under investigation include: Prednisone (DRUG), Mycophenolate mofetil (DRUG), BMS-188667 (BIOLOGICAL), Placebo matching with BMS-188667 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01714817?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01714817's enrollment target sits among peer trials
695 518th of 2000 higher than 1,482 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05417594 · 695 participants · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI